Business

Mesa Laboratories Executes Previously-Announced Strategic Financing Plan

LAKEWOOD, Colo., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate principal of the Company’s 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). On August 12, 2025, the Company drew $97.0 million under its existing Amended and Restated Credit Agreement (the “Credit Agreement”), bringing the total outst

articleMesa Laboratories, Inc.August 18, 20254/company/mesa-laboratories-inc/news/mesa-laboratories-executes-previously-announced-180100463
Mesa Laboratories Executes Previously-Announced Strategic Financing Plan

About this update from Mesa Laboratories, Inc.

[{"type":"image","alt":"Mesa Laboratories, Inc.","displaySize":"","headline":null,"caption":"Mesa Laboratories, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":173,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/7f0a392e2ce47d53cbd422dc4e14c12f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6Zp6_jsAFv5FhAakXT6bNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7f0a392e2ce47d53cbd422dc4e14c12f","width":173,"height":97}},"lazy":false},{"type":"text","content":"LAKEWOOD, Colo., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate principal of the Company’s 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). On August 12, 2025, the Company drew $97.0 million under its existing Amended and Restated Credit Agreement (the “Credit Agreement”), bringing the total outstanding balance to $108 million. The proceeds from the draw were used to settle the 2025 Notes that matured on August 15, 2025.","length":626,"tagName":"p"},{"type":"text","content":""This transaction reflects the disciplined execution of a plan we communicated in April, 2024," said John Sakys, Chief Financial Officer. "We’ve taken deliberate steps to optimize our capital structure using our Credit Facility, reducing potential dilution to our shareholders from the use of a hybrid debt instrument while supporting Mesa’s long-term growth."The interest rate on the Credit Facility, currently 7.18%, will decrease in line with future Federal Funds Rate reductions, along with an additional 25 basis point reduction triggered when Mesa’s net leverage ratio falls below 3.0x which we expect to happen no later than the third quarter of this fiscal year. We expect interest payments for the second quarter of fiscal year 2026 to be approximately $2.7 million, and we expect to make interest payments of $3.1 million or lower in each quarter thereafter, at current outstanding debt levels.","length":926,"tagName":"p"},{"type":"text","content":"Under the definition in our Credit Agreement, total net leverage ratio is defined as the ratio of total debt minus unrestricted cash in excess of $10 million as compared to...

More updates from Mesa Laboratories, Inc.

Mesa Laboratories, Inc.Convertible Notesleverage ratiodebt instrumentsCredit Agreementoutstanding balanceinterest paymentsprincipal paymentsdebt instrumentCredit FacilityCompany